1	Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low- and middle-
2	income countries: a modelling study
3	Han Fu ^{1, 2*} , Kaja Abbas ^{1, 2, 3} , Stefano Malvolti ⁴ , Christopher Gregory ⁵ , Melissa Ko ⁴ , Jean-Pierre Amorij ⁶ , Mark
4	Jit ^{1,2,7}
5	¹ Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London,
6	United Kingdom
7	² Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine,
8	London, United Kingdom
9	³ Public Health Foundation of India, New Delhi, India
10	⁴ MMGH Consulting GmbH, Zurich, Switzerland
11	⁵ Immunization Unit, Programme Division, United Nations Children's Fund (UNICEF), New York, United States
12	⁶ Supply Division, Vaccine Centre, UNICEF, Copenhagen, Denmark
13	⁷ School of Public Health, University of Hong Kong, Hong Kong, SAR, China
14	
15	*Corresponding author
16	E-mail: <u>Han.Fu@lshtm.ac.uk</u> (HF)
17	Address: Keppel Street, London, WC1E 7HT, United Kingdom
18	

19 Abstract

20 Background

21 Microarray patches are a promising technology being developed to reduce barriers to vaccine delivery based 22 on needles and syringes. To address the evidence gap on the public health value of applying this potential 23 technology to immunisation programmes, we evaluated the health impact on measles burden and resulting 24 cost-effectiveness of introducing measles-rubella microarray patches (MR-MAPs) in 70 low- and middle-25 income countries (LMICs). 26 Methods 27 We used an age-structured dynamic model of measles transmission and vaccination to project measles cases, 28 deaths, and disability-adjusted life years during 203022040. Compared to the baseline scenarios with 29 continuing current needle-based immunisation practice, we evaluated the introduction of MR-MAPs under 30 different assumptions on measles vaccine coverage projections and MR-MAP introduction strategies. Costs 31 were calculated based on the ingredients approach, including direct cost of measles treatment, vaccine 32 procurement, and vaccine delivery. Model-based burden and cost estimates were derived for individual 33 countries and country income groups. We compared the incremental cost-effectiveness ratios of introducing 34 MR-MAPs to health opportunity costs. 35 Results 36 MR-MAPs introduction could prevent 27% 237% of measles burden between 2030 2040 in 70 LMICs. The 37 largest health impact could be achieved under lower coverage projection and accelerated introduction 38 strategy, with 39 million measles cases averted. Cost of measles treatment is a key driver of the net cost of 39 introduction. In LMICs with a relatively higher income, introducing MR-MAPs could be a cost-saving 40 intervention due to reduction in measles treatment costs. Compared to country-specific health opportunity 41 costs, introducing MR-MAPs would be cost-effective in 16281% of LMICs, depending on the MR-MAPs 42 procurement price and vaccine coverage projections.

43 Conclusions

44 Introducing MR-MAPs in LMICs can be a cost-effective strategy to revitalise measles immunisation

- 45 programmes with stagnant uptake and reach under-vaccinated children. Sustainable introduction and
- 46 uptake of MR-MAPs has the potential to improve vaccine equity within and between countries and
- 47 accelerate progress towards measles elimination.

48 Introduction

49	As one of the essential childhood immunisations, measles-containing vaccines (MCV) has been
50	recommended by the World Health Organization (WHO) Expanded Programme on Immunisation since
51	1974. ¹ The implementation of measles vaccination has brought substantial health benefits, with an
52	estimated 33 million deaths averted between 200022019. ² Maintaining high coverage (>95%) with two
53	doses of MCV is also recognised as a core strategy for measles elimination. ³ However, the uptake of the first
54	dose of MCV was stagnant at 85% globally over 201122019, while measles outbreaks continued to occur,
55	and measles remained a major public health burden in settings with low MCV coverage. The COVID-19
56	pandemic posed further challenges to national immunisation programmes, as seen in a 5% drop in the global
57	coverage of first-dose MCV from 2019 to 2021. ⁴⁵ The coverage of the second MCV dose has steadily
58	increased and reached 72% in 2020, but its progress varies across countries and has stagnated in the last few
59	years. ⁵
60	Currently, MCVs are delivered via needles and syringes (N&Ss). The traditional N&S presentation requires
61	reconstitution before administration, and reconstituted doses that are not used within six hours are
62	discarded. The delivery of N&S vaccines relies on trained healthcare workers for administration and
63	demands a comprehensive and well-functioning cold chain system for storage and transportation.
64	Addressing barriers to effective vaccine delivery associated with N&S vaccines could reduce global measles
65	burden and accelerate progress in measles elimination.
66	Microarray patches (MAPs), a device containing hundreds to thousands of micro-projections that deliver a
67	vaccine dose into the dermis, has product characteristics that could address the barriers to vaccination
68	presented by N&Ss. MAPs have demonstrated stability under higher temperatures for several vaccines,
69	which reduces cold chain demand and potentially makes it easier to deliver vaccines to hard-to-reach areas. 6
70	⁷ In the absence of needles, injection applicators, and reconstitution devices, MAPs could be operated by
71	minimally trained staff or self-administrated, which may expand the workforce to reach zero-dose children
72	and under-immunised population. ⁸ MAPs are also broadly applicable in routine immunisation (RI)
73	programmes and supplementary immunisation activities (SIAs). In low- and middle-income countries (LMICs),

implementing MAP technology may transform the current delivery of measles and rubella vaccines in
immunisation programmes and better reach under-served populations in remote rural or conflict-affected
areas.⁹⁻¹¹ In May 2020, the Vaccine Innovation Prioritisation Strategy, a three-year collaboration between
Gavi, the Vaccine Alliance, WHO, Bill & Melinda Gates Foundation, United Nations Children's Fund (UNICEF)
and PATH to develop a single integrated framework to evaluate, prioritise, and drive forwards vaccine
product innovations, selected MAPs as one of three technologies for prioritisation for development and
implementation.⁸

As measles and rubella vaccines are jointly administered in most settings, a bivalent measles-rubella MAP 81 (MR-MAP) is considered to have significantly broader use than a monovalent measles MAP.⁹ MR-MAPs 82 83 demonstrated both immunogenicity and safety in preclinical studies in infant rhesus macaques and provided effective protection against wild-type measles challenge.¹² Ongoing Phase I/II trials of MR-MAPs are 84 conducted in The Gambia¹³ and Australia.¹⁴ Despite the early stage of clinical development, economic 85 86 evaluation for MR-MAPs prior to phase III trials helps to determine the public health impact and economic 87 case for further investment in development, as well as identify sources of uncertainties around potential impact and cost-effectiveness to inform directions of data collection in the future.¹⁵ Furthermore, early-88 89 stage economic evaluation can assess key determinants of cost-effectiveness and provide feedback on the 90 MR-MAP product profile.¹⁶

91 In 2021, UNICEF commissioned MMGH Consulting GmbH in partnership with London School of Hygiene and 92 Tropical Medicine and Global Health Visions to conduct an initial Full Value of Vaccine Assessment for MR-93 MAPs, to improve the assessment, decision-making, and communication concerning MR-MAP development, 94 procurement, and implementation particularly for the use in LMICs. Placing end-users and stakeholders at 95 the centre, the Assessment aims to facilitate discussion and coordination between different perspectives and address various impacts on health, economics, and society.¹⁷ Analyses to understand the comprehensive 96 97 value of MR-MAPs, including the total system costs, commercial business case, and needs for market 98 incentives, are available in the report for the (initial) Full Value of Vaccines Assessment of MR-MAPs (DOI will 99 be added once officially released.). As part of the value assessment framework for MR-MAPs, this analysis

- 100 focused on the health impact and cost-effectiveness of introducing MR-MAPs in LMICs, where more than
- 101 90% of global measles cases occur.⁵

102 Methods

103 Study setting

104 We included 70 LMICs in this global analysis of measles burden and vaccination, including 20 low-income

- 105 countries, 35 lower-middle-income countries, and 15 upper-middle-income countries based on the World
- 106 Bank income classification for the 2022 fiscal year.¹⁸ We included all LMICs apart from those having been
- 107 verified for measles elimination and then kept their status until at least 2019 and those LMICs having \geq 95%
- 108 coverage with two doses of MCV and reporting ≤ 5 annual measles cases during 2017–2019. Additionally, we
- 109 excluded countries that were projected to achieve a low level of measles burden in our analysis (see
- 110 'Coverage Forecasts' section), defined as \leq 5 annual cases over 2027–2029 and thus for which introducing
- 111 MR-MAPs after 2030 would be expected to have only marginal benefit in burden reduction (Albania,
- Botswana, Cape Verde, Djibouti, Eritrea, Fiji, Georgia, Guinea, Guinea-Bissau, Jordan, Kazakhstan, Kuwait,
- 113 Kyrgyzstan, Malaysia, Morocco, Mauritius, Rwanda, South Sudan, Thailand, Tonga, and Vanuatu). The full list

of countries included in the analysis can be found in table A in online supplemental file S1.

115 Epidemiological model

116 We assessed the epidemiological impact of MR-MAPs introduction on measles burden in each country using 117 Dynamic Measles Immunisation Calculation Engine (DynaMICE), for which a list of key parameters are 118 included in table B in online supplemental file S1 and a detailed description and application has been published.¹⁹ DynaMICE is an age-structured compartmental model of measles transmission with states for 119 120 people who are susceptible, infectious, recovered, protected by maternal antibodies, and protected by 121 immunisation. Measles transmission between age groups is simulated using country-specific social contact matrices²⁰ with a basic reproduction number of 15.9 based on a systematic review.²¹ Case-fatality risks of 122 123 measles are varied across countries and are relatively higher for children under 5 years old based on a recent 124 review of available data.²²

DynaMICE takes into account MCV coverage, efficacy, age at vaccination, and vaccination history of targeted populations. In the model, RI programmes provide the first (MCV1) and second (MCV2) doses of measles vaccines to children aged 9 months and 16.5 months, respectively. SIAs are regularly scheduled for a

128 population of a selected age range to enhance MCV coverage. We assumed SIA doses are delivered to 129 children regardless of their vaccination history, except for up to 7.7% of children who are unreachable under current vaccination activities.²³ In the model, the efficacy of the first MCV dose increases linearly with the 130 age of vaccine administration²⁴ and receiving two MCV doses provides 98% efficacy.²⁵ Vaccine protection 131 132 was assumed to be all-or-nothing, i.e., to offer complete protection to a proportion of the vaccinated 133 individuals and no protection to the rest. 134 Coverage projection Aligning with the approach used in Global Market Study for MCVs,²⁶ Ko et al. projected global demand for 135 136 MCV doses over 203022040 and developed use cases of MR-MAPs in needle-based immunisation programmes at the country level.²⁷ The forecasts were adapted to coverage inputs and delivery components 137 138 for the scenarios we evaluated in this cost-effectiveness analysis of introducing MR-MAPs. 139 To capture uncertainty in the future uptake of measles vaccination, especially given that countries are 140 rebuilding health services disrupted by the COVID-19 pandemic, 'higher' and 'lower' coverage projections for 141 MCV coverage were considered (table 1). Under the 'higher' coverage projection, current RI coverage for 142 MCV1 and MCV2 is projected to increase by 0.523% per year and capped at 95% or a higher level seen in the 143 country-specific historical coverage; SIAs will take place every 225 years with a 95% coverage of children 144 aged 9259 months and will discontinue when MCV2 coverage exceeds 90% over 3 consecutive years. The 145 growth rate of RI coverage and frequency of SIAs depend on country immunisation programmes. Under the 146 'lower' coverage projection, where a less optimistic perspective is applied to the future programme 147 expansion, projected RI coverage will remain constant at the 2019 level, and SIAs will reach only 85% of 148 children. **MR-MAPs** introduction 149

We modelled the effect of MR-MAPs introduction in partially replacing N&S doses in existing immunisation
 programmes (components A, B, and C in table 1) and reaching additional underserved populations for
 measles vaccination (components D, E, and F). Following the assumptions in the demand forecast analysis,²⁷
 the replacement of N&S doses with MR-MAP doses depends on the different MR-MAPs use cases and on

154 country-specific groupings reflective of the characteristics of their measles and rubella immunisation 155 programmes (table A in online supplemental file S1). In countries where measles-mumps-rubella (MMR) 156 vaccines are widely adopted in their existing immunisation programmes, no MR-MAP doses are anticipated 157 to be used, as implementing separate monovalent mumps vaccines with MR-MAPs is less programmatically 158 feasible. In countries which only partially offer or do not use MMR vaccines, 30% or 80% of the total MCV 159 doses will be replaced with MR-MAPs. In addition, with improved product characteristics, MR-MAPs are 160 assumed to reach extra populations living in hard-to-reach areas and children with missed opportunities for vaccination, with a coverage of 20% through RI activities (delivery components D & E) and 10% through one-161 162 off campaigns (component F) in the targeted populations. The hard-to-reach populations include those in 163 urban slums, security compromised, humanitarian settings, and remote/rural areas, while 2% of children under 2 years old were assumed to experience missed opportunities for measles vaccination.²⁷ 164 165 Two introduction strategies for MR-MAPs across countries were evaluated according to multiple factors, such as vaccine introduction history, disease burden, and funding for immunisation programmes.²⁷ Under 166 167 'sequential' introduction, countries introduce MR-MAPs sequentially over the years between 2030[2040; 168 those with higher measles and rubella burden and better operational and financial states for new vaccine 169 introductions will adopt MR-MAPs in earlier years. Alternatively, 'accelerated' introduction allows countries 170 with the greatest need, based on their MCV1 coverage and disease burden only, to be prioritised for MR-171 MAPs introduction. In figure 1, we present coverage forecasts under the sequential and accelerated 172 strategies for MR-MAPs introduction, higher and lower coverage projection assumptions, and different 173 delivery components (table 1) in the Democratic Republic of the Congo. The coverage forecasts for all 70 174 LMICs are included in online supplemental file S2. 175 Economic costs 176 We took a health provider perspective and ingredients approach in estimating the costs under different MR-177 MAPs scenarios. Table 1 shows unit costs of measles vaccine and treatment by country income level, with all

values inflated to 2020 United States Dollar (USD) using country-specific Gross Domestic Product deflators.²⁸

²⁹ For each scenario, the total cost (treatment cost and vaccination cost) at year t in country i is denoted as:

180
$$tc_{i,t} = c_i^{tx} \times m_{i,t} + \sum_p \left(\left(c_{i,p,RI}^{vac} + c_{i,t,RI}^{del} \right) \times d_{i,t,p,RI} + \left(c_{i,p,SIA}^{vac} + c_{i,SIA}^{del} \right) \times d_{i,t,p,SIA} \right).$$

 c_i^{tx} represents the treatment cost for each measles case, extrapolated from data for countries at the same 181 income level in the literature.³⁰⁻³² p indicates different vaccine types characterised by dose presentation, vial 182 size, and valent type. $c_{i,v,Rl}^{vac}$ and $c_{i,v,SlA}^{vac}$ represent the vaccine procurement prices per dose delivered through 183 184 RI and SIA, with an adjustment of wastage rates specific to the vaccine types. The procurement prices for 185 N&S vaccines were obtained from the Market Information for Access Vaccine Purchase Database over 2016^{[2}2020.³³ Taking the average price of MR N&S vaccines as the baseline, we estimated a potential range 186 187 of prices for MR-MAPs by country income group and eligibility to receive Gavi funds. The lower MR-MAP 188 price reflected the increased manufacturing cost per dose for a single-dose vial compared to a multiple-dose 189 vial, using the price data of hepatitis B vaccines as a proxy. The difference in the cost for a pre-filled syringe 190 compared to a single-dose vial is considered in estimating the upper MR-MAP price, based on the price 191 information from pneumococcal conjugate vaccines (see Text A in online supplemental file S1 for details). $c_{i,t,RI}^{del}$ and $c_{i,SIA}^{del}$ represent the vaccine delivery costs per dose for RI and SIA by income level. The marginal 192 193 cost of delivering one routine MCV1 or MCV2 dose was assumed to increase with country-specific coverage forecasts, as higher coverage levels require extra resources for unvaccinated children having the least access 194 to immunisation services.³⁰ Finally, we multiplied these unit costs by the corresponding DynaMICE model 195 196 estimates of $m_{i,t}$ (the number of measles cases) and $d_{i,t,p,RI}$ and $d_{i,t,p,SIA}$ (the numbers of doses 197 administered through RI and SIAs).

198 Cost-effectiveness

Using DynaMICE, we estimated cases, deaths, disability-adjusted life years (DALYs), and economic costs
under the sequential and accelerated MR-MAPs introduction and the baseline scenario without MR-MAPs.
All the health and cost impact estimates were obtained at the country level and also aggregated by the
World Bank income level.¹⁸ For each country and income group, we calculated the incremental costeffectiveness ratio (ICER) by dividing the total incremental costs by the total averted DALYs over 203022040
between the MR-MAPs introduction scenarios and the baseline scenario. In the main analysis, a discounting
rate of 3% was applied equally for costs and health outcomes. We also evaluated the ICERs under differential

206	discounting, where only cost estimates were discounted at 3%, and health outcomes were not discounted,
207	as recommended in the WHO guidelines for economic evaluation of immunisation programmes. ³⁴ Since
208	GDP-based thresholds are no longer recommended by WHO, 35 we instead used the cost-effectiveness
209	thresholds estimated based on empirical data on the opportunity costs of healthcare expenditure ^{36 37} to
210	determine the cost-effectiveness of introducing MR-MAPs at the country level. As for the income-level ICERs,
211	the thresholds were derived from population-weighted health opportunity costs in countries of the
212	corresponding income groups (figure A in online supplemental file S1). In addition, we calculated the
213	maximum MR-MAP procurement price that each country or income setting could afford to pay for the MR-
214	MAPs introduction while ensuring the introduction is cost-effective (compared with country-specific
215	thresholds based on health opportunity costs). This price calculation was conducted with the assumption
216	that the health gains during 203022040 from preventing measles illness, vaccine wastage rates, and all the
217	other types of costs are held fixed under equal discounting.

219 Results

220 Health impact of MR-MAPs introduction

221 Introduction of MR-MAPs would result in measles burden reductions across all country income levels and 222 assumptions about coverage projections (figure 2). Under the higher coverage projection, 21.3 million cases, 223 197 thousand deaths, and 12.4 million DALYs due to measles are projected to occur over 203022040 across 224 all the study countries if MR-MAPs are not available. Sequential introduction of MR-MAPs will result in 14.4 225 million measles cases, 145 thousand deaths, and 9.01 million DALYs, as accelerated introduction will result in 226 13.9 million measles cases, 139 thousand deaths, and 8.69 million DALYs. Countries in the lower-middle-227 income group contribute most to the global burden. The scale of the cumulative burden under the lower 228 coverage projection is larger than the higher coverage projection, while the relative burden trends between 229 different introduction strategies are similar. Under the lower coverage projection, there are estimated 106 230 million measles cases, 1.15 million deaths, and 74.0 million DALYs if MR-MAPs are not available, and 67.1 231 million measles cases, 750 thousand deaths, and 47.7 million DALYs with accelerated MR-MAPs introduction. 232 Table 3 shows how MR-MAPs introduction will reduce the total measles burden in 70 LMICs over 203022040 233 by 27%237%. At the global level, the relative health impact of introducing MR-MAPs is similar between the 234 'higher' and 'lower' coverage projection assumptions. However, the absolute impact varies, with 6.9627.45 235 million and 31.3238.6 million measles cases being averted by MR-MAP introduction under the higher and 236 lower coverage projection assumptions, respectively. Overall, the accelerated introduction of MR-MAPs in 237 key countries is projected to be more effective in reducing measles burden than the sequential introduction, 238 since those countries with higher burden are more likely to benefit from the early introduction of MR-MAPs. 239 For individual countries, introducing MR-MAPs will result in reduction of health burden over 203022040, 240 although some variation remains within the same income-group level. We further analysed the exceptional 241 countries and scenarios showing increased health burden following the MR-MAPs introduction and found 242 health benefits of MR-MAPs introduction with an extended assessment period. This suggested that a longer 243 time horizon would be needed to observe the complete health impacts of introducing MR-MAPs.

244 Economic cost of MR-MAPs introduction

245 Figure 3 illustrates the breakdown of incremental costs following MR-MAPs introduction, compared to the 246 baseline scenario without MR-MAPs. The introduction of MR-MAPs will reduce costs for the existing 247 immunisation service based on N&S vaccines, which will be partly replaced with MR-MAP doses. However, 248 the reduction will not exceed the increase in costs of purchasing and delivering MR-MAPs, since introducing 249 MR-MAPs will deliver extra doses to children experiencing missed opportunities for vaccination and living in 250 hard-to-reach areas (delivery components D[®]F in table 1). Savings from treating measles-associated illness 251 after the MR-MAPs introduction were seen in all country income groups but relatively small compared to 252 other cost types in the low-income setting. Overall, Introducing MR-MAPs will be cost-saving in the lower-253 middle-income and upper-middle-income settings provided at a lower MR-MAP procurement price under 254 the lower coverage projection assumption (table C in online supplemental file S1) due to avoiding the high 255 costs in these countries associated with measles treatment. In the low-income setting, the total incremental 256 costs will increase across all the scenarios for evaluation. Unlike the MR-MAP price, the introduction 257 strategies had little implications in the scale and direction of incremental costs. At the country level, the 258 incremental costs following the introduction of MR-MAPs show a large variation within the same income 259 group, as a result of country heterogeneities in dose demand, measles burden, and vaccine procurement 260 costs.

261 Cost-effectiveness of MR-MAPs introduction

262 Figure 4 shows the income-group level ICERs of introducing MR-MAPs by different assumptions for 263 discounting, coverage projection, introduction strategy, and MR-MAP price. The ICERs lie between 264 10.621850 USD in the low-income group, -10821100 USD in the lower-middle-income group, and -13421210 265 USD in the upper-middle-income group. Negative ICER values corresponding to settings where it is cost-266 saving to introduce MR-MAPs, are mostly seen in the upper-middle-income group with a lower MR-MAP 267 price. In the lower-middle-income group, introducing MR-MAPs would be cost-effective under the lower 268 coverage projection. Under the higher coverage projection, it would not be cost-effective with an upper MR-269 MAP price using equal discounting but cost-effective using differential discounting. In the low-income group,

270 introducing MR-MAPs would only be cost-effective under the lower coverage projection, regardless of the 271 set price for MR-MAPs. Assumptions about the introduction strategy resulted in smaller variations in the 272 ICER estimates among low-income, lower-middle-income, and upper-middle-income country groups. 273 Evaluating at the country level, we found similarity to the income-level analysis in factors that affect the 274 cost-effectiveness of introducing MR-MAPs. MR-MAPs introduction would be less likely to be cost-effective 275 in countries with a lower income, despite wide variation within each income group (figure B in online 276 supplemental file S1). With a 3% discount rate for both health and cost impacts, the introduction of MR-MAPs over 203022040 is considered cost-effective in 26281% and 16261% of analysed countries under a 277 278 lower and upper price of MR-MAPs, respectively (table 4). Alternatively, when applying differential 279 discounting rates, MR-MAPs introduction would be cost-effective in 30281% and 19271% of countries under 280 a lower and higher assumed price, respectively (table D in online supplemental file S1). The assumptions 281 about coverage projection had the greatest influence on the cost-effectiveness of the MR-MAPs introduction. 282 Meanwhile, the procurement cost for MR-MAPs was influential on its cost-effectiveness in lower-middle-283 income countries. Introducing MR-MAPs will be most cost-effective when provided through accelerated 284 introduction with a lower MR-MAP price. 285 The maximum per MR-MAP dose procurement prices (2020 USD) that ensure the cost-effectiveness of 286 introducing MR-MAPs increase with the income-group level (table 5). The price thresholds for MR-MAPs are 287 consistently higher compared to the corresponding prices for N&S vaccines (table 2). Under the lower 288 coverage projection, the maximum MR-MAP prices are higher because of larger health benefits and savings 289 from averting measles burden. In the low-income and lower-middle-income settings, the price thresholds for 290 MR-MAPs were lower under the accelerated introduction strategy than the sequential strategy. While the 291 accelerated introduction will bring greater health benefits, per-dose vaccine delivery cost will also increase 292 with higher coverage, resulting in overall reduction in cost-effectiveness, particularly several years after the 293 MR-MAPs introduction. As seen in the model-based health and cost impact estimates, the threshold prices 294 across countries also result in great variability. In some countries, introducing MR-MAPs was found not to be 295 cost-effective even if the procurement of MR-MAPs is zero price. These countries mostly have high measles

- vaccine coverage forecasts and only contributed to a small proportion (8%) of the total measles burden in
- the 70 LMICs between 203022040. Moreover, our price threshold analysis did not consider the potential
- 298 reduction in delivery costs for MR-MAPs, which could improve the cost-effectiveness of the MR-MAPs
- 299 introduction.

300 Discussion

301 Our modelling analysis suggests that the introduction of MR-MAPs will bring substantial health benefits over 302 203022040 and is likely to be cost-effective in 16281% of LMICs, depending on the assumptions used. The 303 strategy of accelerating MR-MAPs introduction in high-burden countries generates the largest burden 304 reduction compared to sequential introduction globally, despite requiring delayed introduction in lower-305 burden countries. Assumptions about the underlying MCV coverage growth in the future have a great 306 influence on the magnitude of health impacts from introducing MR-MAPs, where the lower coverage 307 projection resulted in larger numbers of averted cases, deaths, and DALYs. Additionally, among the different 308 types of costs, the cost for treating measles illness has a key role in the total expenditure and savings on 309 treatment costs would surpass the incremental costs for the MR-MAPs introduction, especially in countries 310 with a higher income. For each country, the cost-effectiveness of introducing MR-MAPs will largely depend 311 on the procurement price of a MR-MAP dose. 312 To our knowledge, our study is the first cost-effectiveness assessment at a global scale on the potential 313 impact of the MR-MAP introduction. A previous study by Adhikari et al. found that replacing traditional N&Ss 314 with MAPs for measles immunisation is cost-effective in a hypothetical population, due to cost reductions in cold chains, personnel, injection equipment, and needle disposal.³⁸ However, the detailed cost changes 315 316 following the introduction of MR-MAPs would need more empirical research and data to estimate. Additionally, Adhikari et al. assumed no changes in the total administered doses,³⁸ while we focused on the 317 318 possible integration of MR-MAPs into existing immunisation programmes, with partial penetration of the 319 N&S market and additional vaccine delivery to the populations living in hard-to-reach areas and experiencing 320 missed opportunities of vaccination. We considered both the cost and health aspects of MR-MAPs and 321 included the health benefits of reaching previously under-immunised populations. 322 Assumptions about future coverage projections exert the greatest influence on the health impact of MR-323 MAPs among the assumptions examined in this study. The wide range between the lower and higher 324 coverage projection assumptions aims to reflect the multiple sources of uncertainties around the future 325 progress of national immunisation programmes and measles elimination efforts. The pessimistic lower

326 coverage projection scenario may not capture worst-case situations such as those caused by funding 327 instability, emerging diseases, natural disasters, and political conflicts. Such situations could cause MCV 328 coverage not just to stagnate, but to drop below what has been achieved historically, as seen in the global coverage estimate that reduced from 84% in 2020 to 81% in 2021 following the COVID-19 pandemic.⁵ The 329 330 role of MR-MAPs could be even more critical in measles immunisation when the future performance of 331 immunisation programmes cannot meet the historical levels of coverage. In addition, our analysis shows a 332 potentially substantial impact on measles burden reduction with a 10220% increase in coverage from 333 providing MR-MAPs to populations living in hard-to-reach areas and experiencing missed opportunities for 334 vaccination. With further reach to these under-immunised populations, MR-MAPs would realise even 335 greater benefits in reducing measles burden. 336 To estimate the incremental cost of MR-MAPs introduction, we varied vaccine procurement costs, delivery 337 costs, and measles treatment costs by country income level. However, we assumed that delivery costs were 338 the same for N&Ss and MR-MAPs, which may underestimate the potential of MR-MAPs to save costs from health personnel capacity and cold chain equipment.³⁸ On the other hand, integration of MR-MAPs into 339 340 existing immunisation programmes will require structural changes in staffing and operation. There are 341 uncertainties in estimating the delivery costs of MR-MAPs. Collecting the cost data, even at an early stage of 342 vaccine development and licensure, will be useful in informing the investment case of future introduction. 343 Indirect costs were not systematically included in this study. Patient costs for travel and waiting time during 344 vaccination visits were included in a few original data sources, but productivity costs around the treatment of measles-associated illness were not considered.³⁰ From a societal perspective, including productivity loss 345 346 would make the introduction of MR-MAPs more cost-effective. Although MR-MAPs introduction was not 347 considered cost-effective in some upper-middle-income settings from the perspective of measles burden 348 reduction, their ability to reach under-immunised populations may still drive the introduction in order to 349 reach regional measles elimination goals earlier. Furthermore, the impact of an earlier national/regional 350 measles elimination, with the respective savings including reduced future demand for measles vaccines, was 351 not considered in the cost-effectiveness analysis and may further increase the cost-effectiveness of MR-

352 MAPs introduction.

353 There are other limitations in the cost-effectiveness analysis. First, we estimated the health burden following 354 MR-MAPs introduction based on country-level data and models, but some of the largest disparities in vaccine coverage exist at the subnational level such as in remote rural areas or border regions.³⁹ We did not 355 356 investigate whether subnational targeting of MR-MAPs may achieve most of the coverage improvements at 357 reduced cost. Second, we assessed the health and economic benefits of measles burden reduction following 358 the introduction of MR-MAPs but excluded the concurrent reduction of rubella burden. Taking into account 359 the impact on rubella burden will make the introduction of MR-MAPs more cost-effective. Nonetheless, the 360 additional benefits may not be substantial compared to the reduction in measles burden since rubella is less 361 transmissible and typically less severe than measles. Third, measles control measures apart from vaccination, 362 such as contact tracing, self-quarantine, and post-exposure prophylaxis, were not included in the 363 epidemiological modelling. This may affect both the cost and burden estimates, particularly in countries close to elimination.⁴⁰ However, their effect may be more limited in the high-burden countries that we 364 365 examined. Finally, cost-effectiveness thresholds based on health opportunity costs may be useful in 366 reflecting the value for money from a fixed budget perspective, but the methodology for this estimation has 367 not yet been maturely developed, and only few countries have adopted these thresholds explicitly in decision-making for health policies.⁴¹ Other context-specific considerations may also be decisive factors in 368 369 the funding and implementation of MR-MAPs, and WHO recommends against basing health investment 370 decisions purely on comparison to a cost-effectiveness threshold.^{35 42 43} 371 This early-phase cost-effectiveness analysis was conducted from the perspective of the funder, e.g. the 372 country or pooled procurement donors such as Gavi. The examination of the return to the manufacturer on 373 the investment needed for research and development before MR-MAPs enter the market, and the net 374 present value of MR-MAPs are concurrently developed in the initial Full Value of Vaccines Assessment of 375 MR-MAPs and will be reported (DOI to be added once it is officially released.). Our analysis of the cost-376 effectiveness, including the calculated price thresholds for MR-MAPs, may inform vaccine investment 377 entities such as the Vaccine Innovation Prioritisation Strategy about strategies to increase manufacturers'

378 incentives to develop and market MR-MAPs, in order to achieve the projected health impact. While MR-379 MAPs are still in the early stage of clinical development, this analysis can provide initial but comprehensive 380 evidence that policy makers can apply to understand the potential cost-effectiveness of MR-MAPs at the 381 global and/or national level and consider the implementation of MR-MAPs in their longer-term measles 382 vaccination strategies. 383 In conclusion, this study has shown that there are substantial health benefits from introducing MR-MAPs in 384 LMICs, particularly if countries bearing greater measles burden can be prioritised, as evaluated in the 385 scenario with accelerated introduction. In addition to the reduction in measles burden, MR-MAPs 386 introduction would accelerate progress towards measles elimination through more effectively and equitably 387 reaching underserved populations of children with missed opportunities for vaccination or living in hard-to-388 reach areas. Introducing MR-MAPs is also cost-effective in most LMICs, while external funding from donors 389 could support the MR-MAPs introduction in countries where it is not cost-effective under fixed domestic 390 budgets. Although several assumed features of MR-MAPs are still highly uncertain, this early-stage 391 evaluation can help inform key data gaps in assessing the cost-effectiveness of MR-MAPs, including future 392 MCV coverage assumptions, MR-MAP ability to reach zero-dose and under-immunised children, 393 procurement prices, and country-specific costs for measles treatment and vaccine delivery. Addressing these 394 data gaps will facilitate evidence generation for decision-making on MR-MAPs introductions in LMICs.

395 Data availability statement

- 396 Relevant datasets and computer codes of this analysis are available from the corresponding author on
- reasonable request and will be made public in the GitHub repository once the manuscript is accepted for
- 398 journal publication.
- 399
- 400 Ethics statements
- 401 Patient consent for publication
- 402 Not applicable
- 403 *Ethics approval*
- 404 Not applicable
- 405

406 Acknowledgements

- 407 We thank Simon Procter at London School of Hygiene and Tropical Medicine, Jessica Ochalek at York
- 408 University, and Adam Soble, Thomas Cherian, and Carsten Mantel at MMGH Consulting GmbH for helpful
- discussions. We acknowledge the feedback from members of the External Advisory Group of the initial Full
- 410 Vaccine Value Assessment (iFVVA) for MR-MAPs and the WHO Immunization and Vaccine-related
- 411 Implementation Research Advisory Committee.

412 References

- 413 1. Keja K, Chan C, Hayden G, et al. Expanded programme on immunization. World Health Stat Q 414 1988;41(2):59-63. [published Online First: 1988/01/01] 415 2. Li X, Mukandavire C, Cucunuba ZM, et al. Estimating the health impact of vaccination against ten 416 pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. 417 Lancet 2021;397(10272):398-408. doi: 10.1016/S0140-6736(20)32657-X [published Online First: 418 2021/02/01] 419 3. World Health Organization. Measles vaccines: WHO position paper - April 2017. Weekly Epidemiological 420 *Record* 2017;92(17):205-27. [published Online First: 2017/05/02] 421 4. Causey K, Fullman N, Sorensen RJD, et al. Estimating global and regional disruptions to routine childhood 422 vaccine coverage during the COVID-19 pandemic in 2020: a modelling study. Lancet 2021 doi: 423 10.1016/S0140-6736(21)01337-4 [published Online First: 2021/07/18] 424 5. World Health Organization. Immunization data portal, 2021. 425 6. Forster AH, Witham K, Depelsenaire ACI, et al. Safety, tolerability, and immunogenicity of influenza 426 vaccination with a high-density microarray patch: Results from a randomized, controlled phase I 427 clinical trial. PLoS Med 2020;17(3):e1003024. doi: 10.1371/journal.pmed.1003024 [published Online 428 First: 2020/03/18] 429 7. The Vaccine Innovation Prioritisation Strategy. VIPS phase 2 techinical note: Microarray patches, 2020. 430 8. Gavi, the Vaccine Alliance. Vaccine microarray patches (MAPs): public summary of the VIPS Alliance Action 431 Plan. 2021 432 9. Richardson LC, Moss WJ. Measles and rubella microarray array patches to increase vaccination coverage 433 and achieve measles and rubella elimination in Africa. Pan Afr Med J 2020;35(Suppl 1):3. doi: 434 10.11604/pamj.supp.2020.35.1.19753 [published Online First: 2020/05/07] 435 10. Hasso-Agopsowicz M, Crowcroft N, Biellik R, et al. Accelerating the Development of Measles and Rubella 436 Microarray Patches to Eliminate Measles and Rubella: Recent Progress, Remaining Challenges. Front 437 Public Health 2022;10:809675. doi: 10.3389/fpubh.2022.809675 [published Online First: 2022/03/22] 438 11. Peyraud N, Zehrung D, Jarrahian C, et al. Potential use of microarray patches for vaccine delivery in low-439 and middle-income countries. Vaccine 2019;37(32):4427-34. doi: 10.1016/j.vaccine.2019.03.035 440 [published Online First: 2019/07/03] 441 12. Joyce JC, Carroll TD, Collins ML, et al. A Microneedle Patch for Measles and Rubella Vaccination Is 442 Immunogenic and Protective in Infant Rhesus Macaques. J Infect Dis 2018;218(1):124-32. doi: 443 10.1093/infdis/jiy139 [published Online First: 2018/04/28] 444 13. Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial 2020 [Available from: 445 https://ClinicalTrials.gov/show/NCT04394689 accessed 1 May 2022. 446 14. Vaxxas Pty Ltd. First-in-human study to investigate the skin tolerability of micro-projection array patches 447 coated with live attenuated measles and rubella vaccine in healthy adult volunteers: 448 https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000820808, 2021. 449 15. Newall AT, Beutels P, Tuffaha HW, et al. How can early stage economic evaluation help guide research 450 for future vaccines? Vaccine 2022;40(2):175-77. doi: 10.1016/j.vaccine.2021.11.017 [published 451 Online First: 2021/12/07] 452 16. World Health Organization, United Nations Children's Fund. Measles-rubella microarray patch (MR-MAP) 453 target product profile. Switzerland, 2019. 454 17. Hutubessy RCW, Lauer JA, Giersing B, et al. The Full Value of Vaccine Assessments (FVVA): A Framework 455 to Assess and Communicate the Value of Vaccines for Investment and Introduction Decision Making. 456 SSRN 2021 doi: https://dx.doi.org/10.2139/ssrn.3841999 [published Online First: May 7] 457 18. The World Bank. World Bank Country and Lending Groups. 458 19. Fu H, Abbas K, Klepac P, et al. Effect of evidence updates on key determinants of measles vaccination 459 impact: a DynaMICE modelling study in ten high-burden countries. BMC Med 2021;19(1):281. doi: 460 10.1186/s12916-021-02157-4 [published Online First: 2021/11/18] 461 20. Prem K, van Zandvoort K, Klepac P, et al. Projecting contact matrices in 177 geographical regions: an 462 update and comparison with empirical data for the COVID-19 era. Plos Comput Bio
 - 21

463 2021;17(7):e1009098. doi: 10.1371/journal.pcbi.1009098 [published Online First: 2021/07/26] 464 21. Guerra FM, Bolotin S, Lim G, et al. The basic reproduction number (R0) of measles: a systematic review. 465 Lancet Infect Dis 2017;17(12):e420-e28. doi: 10.1016/S1473-3099(17)30307-9 [published Online 466 First: 2017/08/02] 467 22. Portnoy A, Jit M, Ferrari M, et al. Estimates of case-fatality ratios of measles in low-income and middle-468 income countries: a systematic review and modelling analysis. Lancet Glob Health 2019;7(4):e472-469 e81. doi: 10.1016/S2214-109X(18)30537-0 [published Online First: 2019/02/25] 470 23. Cata-Preta BO, Santos TM, Mengistu T, et al. Zero-dose children and the immunisation cascade: 471 Understanding immunisation pathways in low and middle-income countries. Vaccine 472 2021;39(32):4564-70. doi: 10.1016/j.vaccine.2021.02.072 [published Online First: 2021/03/22] 473 24. Hughes SL, Bolotin S, Khan S, et al. The effect of time since measles vaccination and age at first dose on 474 measles vaccine effectiveness - A systematic review. Vaccine 2020;38(3):460-69. doi: 475 10.1016/j.vaccine.2019.10.090 [published Online First: 2019/11/17] 476 25. Sudfeld CR, Navar AM, Halsey NA. Effectiveness of measles vaccination and vitamin A treatment. Int J 477 *Epidemiol* 2010;39 Suppl 1:i48-55. doi: 10.1093/ije/dyq021 [published Online First: 2010/04/02] 478 26. World Health Organization. Global market study: measles-containing vacclines (MCV), 2020. 479 27. Ko M, Malvoti S, Cherian T, et al. Estimating the future global dose demand for Measles-Rubella 480 microarray patches. *medRxiv* 2022:2022.08.11.22278665. doi: 10.1101/2022.08.11.22278665 481 28. The World Bank. GDP deflator (base year varies by country). 1960-2020. 482 29. Turner HC, Lauer JA, Tran BX, et al. Adjusting for Inflation and Currency Changes Within Health Economic 483 Studies. Value Health 2019;22(9):1026-32. doi: 10.1016/j.jval.2019.03.021 [published Online First: 484 2019/06/14] 485 30. Levin A, Burgess C, Garrison LP, Jr., et al. Global eradication of measles: an epidemiologic and economic 486 evaluation. J Infect Dis 2011;204 Suppl 1:S98-106. doi: 10.1093/infdis/jir096 [published Online First: 487 2011/06/17] 488 31. Hyle EP, Fields NF, Fiebelkorn AP, et al. The Clinical Impact and Cost-effectiveness of Measles-Mumps-489 Rubella Vaccination to Prevent Measles Importations Among International Travelers From the 490 United States. Clin Infect Dis 2019;69(2):306-15. doi: 10.1093/cid/ciy861 [published Online First: 491 2018/10/13] 492 32. Njau J, Janta D, Stanescu A, et al. Assessment of Economic Burden of Concurrent Measles and Rubella 493 Outbreaks, Romania, 2011-2012. Emerging infectious diseases 2019;25(6):1101-09. doi: 10.3201/eid2506.180339 [published Online First: 2019/05/21] 494 495 33. World Health Organization. MI4A Vaccine Purchase Database. 496 34. World Health Organization. WHO guide for standardization of economic evaluations of immunization 497 programmes. 2nd ed. Geneva, 2019. 498 35. Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bulletin of the 499 World Health Organization 2016;94(12):925-30. doi: 10.2471/BLT.15.164418 [published Online First: 500 2016/12/21] 501 36. Lomas J, Claxton K, Ochalek J. Accounting for country- and time-specific values in the economic 502 evaluation of health-related projects relevant to low- and middle-income countries. Health Policy 503 Plan 2022;37(1):45-54. doi: 10.1093/heapol/czab104 [published Online First: 2021/08/20] 504 37. Ochalek J, Lomas J. Reflecting the Health Opportunity Costs of Funding Decisions Within Value 505 Frameworks: Initial Estimates and the Need for Further Research. Clin Ther 2020;42(1):44-59 e2. doi: 506 10.1016/j.clinthera.2019.12.002 [published Online First: 2020/01/21] 38. Adhikari BB, Goodson JL, Chu SY, et al. Assessing the Potential Cost-Effectiveness of Microneedle Patches 507 508 in Childhood Measles Vaccination Programs: The Case for Further Research and Development. Drugs 509 R D 2016;16(4):327-38. doi: 10.1007/s40268-016-0144-x [published Online First: 2016/10/04] 39. Local Burden of Disease Vaccine Coverage C. Mapping routine measles vaccination in low- and middle-510 511 income countries. Nature 2020 doi: 10.1038/s41586-020-03043-4 [published Online First: 512 2020/12/18] 513 40. Enanoria WT, Liu F, Zipprich J, et al. The Effect of Contact Investigations and Public Health Interventions

514	in the Control and Prevention of Measles Transmission: A Simulation Study. <i>PloS one</i>
515	2016;11(12):e0167160. doi: 10.1371/journal.pone.0167160 [published Online First: 2016/12/13]
516	41. Thokala P, Ochalek J, Leech AA, et al. Cost-Effectiveness Thresholds: the Past, the Present and the Future.
517	<i>Pharmacoeconomics</i> 2018;36(5):509-22. doi: 10.1007/s40273-017-0606-1 [published Online First:
518	2018/02/11]
519	42. World Health Organization. WHO Evidence Considerations for Vaccine Policy Development (ECVP):
520	generic framework for vaccines/monoclonal antibodies in development. In: Immunization VaB, ed.,
521	2022.
522	43. Kochhar S, Barreira D, Beattie P, et al. Building the concept for WHO Evidence Considerations for Vaccine
523	Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case. Vaccine
524	2022;40(12):1681-90. doi: 10.1016/j.vaccine.2021.10.062 [published Online First: 2022/02/16]

526 Tables

527 Table 1. Assumptions for coverage forecasts and delivery components of measles vaccines

528 Measles vaccine delivery is modelled through six components (A to F) with different age and vaccination

- 529 status of target populations, coverage projection assumptions, delivery approaches (RI or campaign), and
- 530 dose presentations (N&S or MR-MAP). Details of the parameters and data sources used in shaping these
- assumptions are included in the demand forecast analysis by Ko et al.²⁷. Introducing MR-MAPs was assumed
- to partially replace doses in the existing needle-based immunisation programmes with MR-MAPs
- 533 (components A, B, and C) and provide additional MR-MAP doses to children with MOV or living in HTR areas
- 534 (components D, E, and F). The level of replacement with MR-MAPs (market penetration) depends on the size
- of the different use cases for MR-MAPs and the characteristics of the measles and rubella programmes
- 536 (inclusive of the use of MMR N&S vaccines) in each country. Abbreviations: HTR-hard-to-reach, MCV1-the
- 537 first routine dose of measles-containing vaccine, MCV2-the second routine dose of measles-containing
- 538 vaccine, MMR-measles-mumps-rubella, MOV-missed opportunities for vaccination, MR-MAP-measles-
- rubella microarray patch, N&S-needle and syringe, RI-routine immunisation, SIA-supplementary
- 540 immunisation activity.

Delivery components and	Coverage projection of target	Effect of MR-MAPs	
target population	'Higher' coverage	'Lower' coverage	
A: MCV1 for children aged 9 months old, RI B: MCV2 for children aged 16.5 months old, RI	 Annual growth depending on the overall coverage level: 3% per year for <70% 1% per year for 70285% 0.5% per year for >85% capped at 95% or a higher level shown in the past programme 	Stagnant coverage estimates at the 2019 level	Replace a country- specific proportion of N&S doses: - 0% for major MMR use in their immunisation programmes - 30% for partial
C: SIA coverage for children aged 9259 months old, campaign	 Frequency depending on MCV2 coverage: every 2 years for <60% every 3 years for 60280% every 425 years for >80% discontinuation for >90% over 3 consecutive years Fixed coverage: 95% 	Frequency is the same as under the 'higher' coverage projection assumptions. Fixed coverage of 85%	MMR use - 80% for no MMR use
D: MCV1 for children aged 122 years old with MOV or living in HTR areas, RI E: MCV2 for children aged 122 years old with MOV or living in HTR areas, RI	Fixed coverage: 20% of childre or living in HTR areas	n experiencing MOV	Reach additional populations that were assumed not being reached with the N&S vaccines
F: One-time catch-up SIA for population aged 2015 years old with MOV or living in HTR areas, campaign	Fixed coverage: 10% of childre or living in HTR areas	n experiencing MOV	-

541 Table 2. Unit costs (2020 USD) for measles vaccination and treatment by income level of countries

- 542 Unit costs per vaccine dose or per measles case are listed by income level and other factors specific to the type of costs. N&S vaccine procurement prices
- 543 were extracted from the Market Information for Access Vaccine Purchase Database³³ by taking the median prices over 2016 2020, while MR-MAP prices
- 544 were estimated using the N&S prices plus potential increases in manufacturing costs (text A in online supplemental file S1). Wastage rates were specified by
- dose package and delivery approaches (RI or SIA) and applied to adjust vaccine price, as: procurement price / (1- wastage rate). Vaccine delivery costs are
- 546 dependent on delivery approaches,³⁰ for RI, marginal delivery cost increases with baseline coverage since more resources are required to reach the
- 547 underserved populations. Costs for treating measles-related illness were extracted from countries with available data through a literature review (text B in
- online supplemental file S1). Abbreviations: MAPs-microarray patches, MI4A-Market Information for Access, MMR-measles-mumps-rubella, MR-measles-
- rubella, N&S-needle and syringe, RI-routine immunisation, USD-United States dollar.

Cost type (per dose or per case)	Low income	Lower middle income	Upper middle income	Source and notes
N&S wastage-	<u>Gavi-eligible countries, MR:</u>	<u>Gavi, MR:</u>	MR:	MI4A ³³
adjusted price, RI	0.73/(1-0.15) = 0.86 (5-dose vial)	0.82/(1-0.15) = 0.96 (5-dose vial)	2.37/(1-0.01) = 2.39 (1-dose vial)	1-dose vial: 1% wastage
	0.66/(1-0.4) = 1.10 (10-dose vial)	0.66/(1-0.4) = 1.10 (10-dose vial)	0.69/(1-0.15) = 0.81 (5-dose vial)*	2-dose vial: 1% wastage
			0.69/(1-0.4) = 1.15 (10-dose vial)	5-dose vial: 15% wastage
		<u>Non-Gavi, MR:</u>		10-dose vial: 40% wastage
		0.87/(1-0.15) = 1.02 (5-dose vial)	<u>MMR:</u>	
		0.70/(1-0.4) = 1.17 (10-dose vial)	4.00/(1-0.01) = 4.04 (1-dose vial)*	*Prices from vials with a
			4.00/(1-0.01) = 4.04 (2-dose vial)	higher dose were used to
		<u>Non-Gavi, MMR:</u>	1.50/(1-0.15) = 1.76 (5-dose vial)*	ensure the inverse
		4.47/(1-0.01) = 4.52 (2-dose vial)	1.50/(1-0.4) = 2.50 (10-dose vial)	relationship between vial
				doses and costs.
N&S wastage-	<u>Gavi, MR:</u>	<u>Gavi, MR:</u>	MR:	MI4A ³³
adjusted price,	0.73/(1-0.1) = 0.81 (5-dose vial)	0.82/(1-0.1) = 0.91 (5-dose vial)	2.37/(1-0.01) = 2.39 (1-dose vial)	1-dose vial: 1% wastage
campaign	0.66/(1-0.1) = 0.73 (10-dose vial)	0.66/(1-0.1) = 0.73 (10-dose vial)	0.69/(1-0.1) = 0.77 (5-dose vial)*	2-dose vial: 1% wastage
			0.69/(1-0.1) = 0.77 (10-dose vial)	5-dose vial: 10% wastage
		<u>Non-Gavi, MR:</u>		10-dose vial: 10% wastage
		0.87/(1-0.1) = 0.97 (5-dose vial)	<u>MMR:</u>	
		0.70/(1-0.1) = 0.78 (10-dose vial)	4.00/(1-0.01) = 4.04 (1-dose vial)*	*Prices from vials with a
			4.00/(1-0.01) = 4.04 (2-dose vial)	higher dose were used to
		<u>Non-Gavi, MMR:</u>	1.50/(1-0.1) = 1.67 (5-dose vial)*	ensure the inverse
		4.47/(1-0.01) = 4.52 (2-dose vial)	1.50/(1-0.1) = 1.67 (10-dose vial)	relationship between vial
				doses and costs.

MR-MAP	1.29/(1-0.01) = 1.30 (lower)	<u>Gavi:</u>	2.63/(1-0.01) = 2.66 (lower)	1-dose vial: 1% wastage
wastage-adjusted	2.92/(1-0.01) = 2.95 (upper)	1.29/(1-0.01) = 1.30 (lower)	5.20/(1-0.01) = 5.25 (upper)	See text A in online
price, RI and		2.92/(1-0.01) = 2.95 (upper)		supplemental file S1
campaign				
		<u>Non-Gavi:</u>		
		1.48/(1-0.01) = 1.49 (lower)		
		3.36/(1-0.01) = 3.39 (upper)		
Vaccine delivery	2.02 plus	5.11 plus	6.45	Levin et al. ³⁰
cost, RI	0.071 and 0.148 per 1% coverage	0.177 and 0.272 per 1% coverage		Baseline coverage is set as
	increase for baseline coverage	increase for baseline coverage		2020 projected coverage.
	<80% and >=80%	<80% and >=80%		
Vaccine delivery	0.91	1.89	1.97	Levin et al. ³⁰
cost, campaign				
Measles	10.9	120	235	See text B in online
treatment cost				supplemental file S1

550

551

552 Table 3. Averted measles burden (in thousands) following the introduction of MR-MAPs

553 Numbers represent the absolute cases, deaths, and DALYs averted in thousands. Percentages in the brackets show the relative burden reduction compared

to the scenarios without MR-MAPs. Abbreviations: DALY-disability-adjusted life year, MR-MAP-measles-rubella microarray patch.

Projection assumption			Higher c	overage					Low er co	overage		
Introduction strategy	Sequential			Accelerated			Sequential			Accelerated		
Measurement	Cases	Deaths	DALYs	Cases	Deaths	DALYs	Cases	Deaths	DALYs	Cases	Deaths	DALYs
Low income	1076	11.4	742	1116	11.3	739	13004	164	11075	14465	176	11851
Low income	(20.4%)	(22.6%)	(22.2%)	(21.1%)	(22.5%)	(22.1%)	(36.7%)	(38.3%)	(38.6%)	(40.8%)	(41.2%)	(41.3%)
Lower middle income	5000	38.1	2494	5452	43.4	2815	16905	218	13612	23063	220	14014
Lower middle income	(34.2%)	(27.0%)	(28.6%)	(37.3%)	(30.8%)	(32.3%)	(26.5%)	(31.9%)	(31.7%)	(36.2%)	(32.1%)	(32.7%)
Linn au middla in com a	887	2.85	185	884	2.83	184	1350	7.70	517	1094	5.88	395
Upper middle income	(61.9%)	(50.7%)	(50.7%)	(61.7%)	(50.4%)	(50.4%)	(20.8%)	(21.7%)	(21.9%)	(16.9%)	(16.6%)	(16.8%)
Tatal	6963	52.3	3420	7452	57.6	3737	31259	390	25204	38623	402	26260
Total	(32.7%)	(26.6%)	(27.5%)	(35.0%)	(29.2%)	(30.1%)	(29.6%)	(34.0%)	(34.1%)	(36.5%)	(35.0%)	(35.5%)

medRxiv preprint doi: https://doi.org/10.1101/2023.03.10.23287067; this version posted March 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

556 Table 4. Number of countries where introducing MR-MAPs is cost-effective

557 Introducing MR-MAPs is considered to be cost-effective if the country-specific ICER is below the country-

specific threshold, under a 3% annual discount rate on both cost and health benefits. Abbreviations: ICER-

559 incremental cost-effectiveness ratio, MR-MAP-measles-rubella microarray patch.

Projection assumption	Higher c	overage			Lower c	overage		
Introduction strategy	Sequential		Accelera	Accelerated		Sequential		ated
MR-MAP price	Lower	Upper	Low er	Upper	Lower	Upper	Lower	Upper
Low income	3/20	0/20	3/20	0/20	17/20	9/20	18/20	10/20
Lower middle income	10/35	6/35	9/35	5/35	25/35	20/35	28/35	22/35
Upper middle income	5/15	5/15	7/15	6/15	11/15	11/15	11/15	11/15
Total	18/70	11/70	19/70	11/70	53/70	40/70	57/70	43/70

⁵⁶⁰

561

562 **Table 5. Wastage-adjusted MR-MAP price thresholds (2020 USD) for introducing MR-MAPs to be** 563 **cost-effective**

564 Numbers represent the wastage-adjusted price thresholds for introducing MR-MAP to be cost-effective at

565 the income-group and the country level by different coverage projection assumptions and introduction

strategies. At the country level, the ranges of price thresholds are presented, with *n* in the brackets denoting

567 the number of countries except for those where introducing MR-MAPs will not be cost-effective even if the

568 procurement of MR-MAPs is at zero cost. The price thresholds were calculated while the health burden

569 estimates, vaccine wastage rates, and other cost inputs were assumed fixed. If an MR-MAP dose is provided

at a procurement price above the threshold, it implies that introducing MR-MAPs would not be cost-

571 effective. Abbreviation: MR-MAP-measles-rubella microarray patch.

Projection assumption	Higher o	coverage	Lower coverage			
Introduction strategy	Sequential	Accelerated	Sequential	Accelerated		
Low income						
Income-group level	0.764	0.709	5.89	5.47		
Country level	0.123ิ2.32 (n = 19)	0.041ิ2.51 (n = 19)	0.397⊡18.1 (n = 19)	0.586⊡18.1 (n = 19)		
Lower middle income						
Income-group level	2.67	2.17	14.7	11.6		
Country level	0.012237.9 (n = 25)	0.051⊡40.7 (n = 27)	0.086⊡39.6 (n = 31)	0.572₽72.0 (n = 29)		
Upper middle income						
Income-group level	23.9	27.4	76.6	67.2		
Country level	0.658⊡353 (n = 10)	0.635ิ2389 (n = 9)	0.58623310 (n = 12)	0.57921730 (n = 12)		

573 Figure captions

574 Figure 1. Coverage forecasts of measles vaccination by delivery components in the Democratic 575 Republic of the Congo

Annual measles vaccine coverage forecasts through delivery components A^IF (Table 1) are presented for the
Democratic Republic of the Congo over 2020^I2040. Circles with different colours show the coverage by
scenarios, and vertical dashed lines represent the introduction years under the sequential (green) and
accelerated (red) introduction. For components A^IC, coverage forecasts for the existing immunisation

- 580 programmes (blue) are the same regardless of MR-MAPs introduction but different for higher (darker
- colours) and lower (lighter colours) coverage projection assumptions. These coverage forecasts refer to the
- 582 proportions of the total population in the corresponding age groups. For components D^DF, the coverage
- forecasts refer to the proportions of children experiencing MOV or living in HTR areas that receive additional
- 584 MR-MAP doses, and fixed coverage is assumed. Abbreviations: HTR-hard-to-reach, MCV1-the first routine
- dose of measles-containing vaccine, MCV2-the second routine dose of measles-containing vaccine, MOV-
- 586 missed opportunities for vaccination, MR-MAP-measles-rubella microarray patch.

587

588 Figure 2. Cumulative measles burden (in millions) by coverage projections and income levels

- 589 Bars represent the total estimated measles cases, deaths, and DALYs in millions over 203022040 by income
- 590 levels, with darker and lighter colours showing the results under higher and lower coverage assumptions,
- respectively. Abbreviations: DALY-disability-adjusted life year, MAP-microarray patch, MR-measles-rubella.

592

593 Figure 3. Breakdown of incremental costs following MR-MAPs introduction

594 The upper and lower panels show the incremental costs under higher and lower coverage projection

- assumptions, respectively. For each horizontal bar, incremental costs of measles treatment, vaccine
- 596 procurement, and vaccine delivery are stacked and denoted in different colours. Hollow circles represent
- 597 overall incremental costs. The vertical line is set at zero; to its left, negative values (purple and yellow bars)
- 598 indicate savings following the MR-MAPs introduction, while to its right, positive values (green bars) indicate
- 599 increased costs. Abbreviations: DALY-disability-adjusted life year, MR-MAP-measles-rubella microarray patch.

600

601 Figure 4. Incremental cost-effectiveness ratios of introducing MR-MAPs

602 Income-group level ICERs of introducing MR-MAPs are presented by discounting approaches. Equal

discounting applies a 3% rate to both costs and health outcomes (averted DALYs), while differential

604 discounting applies a 3% rate only to costs and no discounting of health outcomes. Circles and triangles

- 605 denote the ICERs with a lower and upper MR-MAP price, respectively. Colours represent the sequential
- 606 (green) and accelerated (red) introduction strategies and assumptions of higher (darker) and lower (lighter)
- 607 coverage projections. Horizontal dashed lines indicate the cost-effectiveness thresholds at the income-group
- 608 level; for scenarios with an ICER below the lines, it would be cost-effective to introduce MR-MAPs.
- 609 Abbreviations: DALY-disability-adjusted life years, ICER-incremental cost-effectiveness ratio, MR-MAP-
- 610 measles-rubella microarray patch.

612 Funding

- This work is part of the initial Full Vaccine Value Assessment (iFVVA) for MR-MAPs, which is funded by
- 614 UNICEF and Al Waleed Philanthropies (grant number 43317323). HF, KA, and MJ from the London School of
- 615 Hygiene & Tropical Medicine receive funding support from the Bill and Melinda Gates Foundation via the
- 616 Vaccine Impact Modelling Consortium (grant number INV-009125). The authors alone are responsible for the
- 617 views expressed in the article and they do not necessarily represent the views, decisions or policies of the
- funders and the institutions with which they are affiliated. The funders had no role in the study design, data
- 619 collection and analysis, decision to publish, or preparation of the manuscript.
- 620
- 621 Competing interests
- 622 None declared.
- 623
- 624 Supplementary Files


625 **Online supplemental file S1. Supplementary methods and results.** Text A. Estimating the theoretical price

ranges for MR-MAPs. Text B. Cost of treating a measles case. Table A. List of 70 countries and related inputs


627 included in the study. Table B. DynaMICE model parameters. Table C. Incremental cost (in million USD) of


628 introducing MR-MAPs by income groups, coverage assumptions, and the MR-MAP prices. Table D. Number

- 629 of countries where introducing MR-MAPs is cost-effective under differential discounting. Figure A. Health
- 630 opportunity costs in 70 low- and middle-income countries. Figure B. Net health benefits of introducing MR-
- 631 MAPs in 70 countries under the equal discounting assumption.
- 632 Online supplemental file S2. Coverage forecasts and delivery components in 70 countries.




- Accelerated MR–MAPs intro (higher cov)
- Accelerated MR–MAPs intro (lower cov)








Higher coverage projection




Lower coverage projection







Differential discounting



MR–MAP price • Lower price • Upper price